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The association of protease inhibitors (PI) to antiretroviral 
therapy has generated sensible changes in morbidity and 
mortality of HIV-infected patients. Aim: Aims at evaluating the 
impact of this association on the prevalence of rhinosinusitis 
(RS) and CD4+ lymphocyte count in HIV-infected children. 
Methods: Retrospective cross-sectional study of the medical 
charts of 471 HIV-infected children. In 1996, protease 
inhibitors were approved for use as an association drug in 
antiretroviral therapy. Children were divided into two groups: 
one which did not receive PI and another which received 
PI after 1996. The prevalence of RS and CD4+ lymphocyte 
counts were compared between these groups. Results: 
14.4% of HIV-infected children had RS. Chronic RS was more 
prevalent the its acute counterpart. Children under 6 years 
old who were taking protease inhibitors presented with a 
significant higher prevalence of acute RS. The association of 
PI with the antiretroviral regimen was associated to higher 
mean CD4+ lymphocyte count and lower prevalence of 
chronic RS. Conclusions: The use of protease inhibitors was 
associated to higher mean CD4+ lymphocyte count. Children 
under 6 years of age in antiretroviral therapy associated with 
PI presented a lower likelihood of developing chronic RS.
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INTRODUCTION
Worldwide dissemination of the Human Immu-
nodefficiency Virus (HIV) has had a terrible impact on 
children. Based on 20041 data, the UNAIDS/WHO has 
estimated that 2.2 million children aged below 15 years 
are infected. The Brazilian Ministry of Health reported 13 
786 cases in children aged below 13 years by December 
2004.2 The advent of new antiretroviral drugs, especially 
protease inhibitors, has substantially reduced the mortality 
and increased the life expectancy of these children.3,4 This 
disease, together with the fact that many of the initial signs 
and symptoms of HIV infection occur in the ear, nose and 
throat, has meant that many such patients are brought in 
for assessment by otorhinolaryngolotists.3,5,6
Children generally present six to eight upper respi-
ratory virus infections a year.7 About 5% to 13% of these 
episodes progress to secondary bacterial rhinosinusitis.8 
Most of these children that develop a bacterial infection 
respond well to medication. Some, however, progress to 
chronic rhinosinusitis, particularly those with a dysfunc-
tion of nasosinusal physiology or any type of immune 
deficiency. HIV-infected patients are at an increased risk 
of developing chronic rhinosinusitis.9
Zidovudine, a nucleoside reverse transcriptase 
inhibitor (NRTI), was developed in 1987, and became 
the first medication for the Acquired Immunodefficiency 
Syndrome (AIDS). Non-nucleoside reverse transcriptase 
inhibitors (NNRTI) were developed next. In 1996, new 
antiretroviral drugs - the protease inhibitors (PI) - were 
introduced.3 The association of these new drugs (usually 
2 NRTI + 1 PI or 1 NRTI + 1NNRTI + 1PI) is known as the 
Highly Active Antiretroviral Therapy (HAART).
Although rhinosinusitis is more prevalent in HIV-
infected children, data on changes in the prevalence 
of this disease in children after HAART was introduced 
remain sparse.
Thus, the purpose of this study was to assess chan-
ges in the prevalence and pattern of rhinosinusitis and 
CD4+ lymphocyte serum counts in a specific population 
of Brazilian HIV-infected children following the introduc-
tion of HAART.
MATERIAL AND METHOD
A cross-sectional study model was used to retros-
pectively review the files of 471 children aged from 0 to 12 
years and 11 months with a prior diagnosis of HIV-infection 
seen at the HIV/AIDS Outpatient Unit from January 1990 
to December 2004. Data analysis for this study was un-
dertaken from January 1990 to December 2004; however, 
follow-up of these and new cases of HIV-infected children 
continues to done in our outpatient unit. The Research 
Ethics Committee of our institution approved the study 
(protocol number 153/03).
All children aged from 0 to 12 years and 11 months 
bearing a serological diagnosis of HIV infection (positive 
Elisa and/or Western Blot tests) that were seen at the ou-
tpatient unit from January 1990 to December 2004 were 
included in this study. Exclusion criteria were absence 
or irregular use of antiretroviral therapy or use of one 
or more antiretroviral drugs during 4 months or less. 
Twelve children were excluded from the sample. The 
459 children included in the study were divided into two 
groups, as follows: those using regimens without protea-
se inhibitors (Anti-Retroviral Therapy - ART) totaling 236 
children, and those using HAART totaling 223 children. 
The mean duration of therapy among patients given ART 
was 14 ±4 months; among patients given HAART it was 
9 ±2 months.
The same specialist (IDM) undertook a complete 
otorhinolaryngological physical examination in the first 
ambulatory visit. Rhinosinusitis was diagnosed and classi-
fied into acute and chronic forms according to the 1998 I 
Brazilian Consensus on Rhinosinusitis of the ABORL-CCF (I 
Consenso Brasileiro sobre Rhinosinusitis da ABORL-CCF). 
Thus, acute rhinosinusitis was diagnosed when children 
presented:10
a) A compatible medical history, duration up to 4 
weeks (nose block, yellowish rhinorrhea, fever, headache, 
coughing and/or oropharyngeal irritation).
b) A suggestive physical examination (mucosal 
edema and hyperemia, purulent discharge in the nose, 
oropharyngeal secretion originating in the rhinopharynx 
and/or pain on palpating the area of the sinuses).
c) A plain radiograph of the paranasal sinuses in 
orthostatism (showing mucosal edema and/or sinus opa-
cification).
Children were diagnosed as having chronic rhino-
sinusitis when presenting:10
a) A compatible medical history, duration over 4 
weeks (yellowish rhinorrhea, coughing, cacosmia and/or 
feeling of heaviness in the head).
b) A suggestive physical examination (nasal and/
or retronasal purulent discharge).
c) Computed tomography of the paranasal sinuses 
(mucosal edema, opacification of sinuses and/or nasal 
cavity).
Some children underwent nasofibrolaryngoscopy, 
although this exam was not done routinely. A blood sample 
was taken to measure the serum CD4+ lymphocyte count 
on the same day of consultation.
Statistical analysis: Analysis of the 459 children 
was stratified by age, subdivided into two groups: 0 to 5 
years and 11 months, and 6 to 12 years and 11 months. 
We calculated and compared the prevalence of rhinosi-
nusitis in each age group, and the CD4+ T lymphocyte 
counts among ART and HAART patients. We applied the 
Pearson chi-square test and the Fisher exact test for cate-
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gorical variables. For continuous variables we applied the 
Student t test for independent samples when there was 
homocedasticity and equality of variances; otherwise we 
used the non-parametric Mann-Whitney U test. P values 
below 0.05 were considered statistically significant. The 
software Statistical Package for Social Sciences (SPSS® 
for Windows 10.0, SPSS Inc., Chicago, IL) was used for 
data analysis.
RESULTS
Table 1 shows demographic data (age, sex, origin 
and HIV infection route) and the antiretroviral regimens 
given to the 459 children. Immunological classification data 
about the children were taken from their medical files, and 
were based on the 1994 Center for Disease Control Revi-
sed Classification System for Human Immunodeficiency 
Infection in Children Less than 13 Years of Age,11 these 
are summarized in Table 2. Among the 459 children, 66 
(14.4%) presented rhinosinusitis, of which 24 (13.6%) were 
aged below 5 years and 11 months, and 42 (14.8%) were 
aged from 6 to 12 years and 11 months (p = 0.8). Thirty-
six children (7.8%) presented chronic rhinosinusitis, and 
30 children (6.5%) presented acute rhinosinusitis. Chronic 
rhinosinusitis was more prevalent in both age groups.
Table 3 shows the prevalences of rhinosinusitis 
and the distribution according to age and use of HAART. 
Among children aged from 0 to 5 years and 11 months, 
those that were given HAART had a higher prevalence of 
acute rhinosinusitis (12.9% vs. 1.9%, p=0.007). The rela-
tive risk of HAART-treated children aged below 5 years 
and 11 months of presenting acute rhinosinusitis was 2.2 
times (95% CI: 1.6 - 3.1) the risk of ART-treated children 
presenting the same condition. The observed differences 
in the prevalence of chronic rhinosinusitis were not sta-
tistically significant.
There were no statistically significant differences on 
the prevalences of acute and chronic rhinosinusitis among 
children given HAART and children given ART in the 6 to 
12 years and 11 months age group.
Table 1. Data on demography and antiretroviral regimens in 459 
HIV-infected children.
Sex
Male 258 (56.2%)
Female     201 (43.8%)
Age
Mean ± Standard deviation 
(years)
6.6 ± 2.5
0 to 5 years and 11 months 176 (38.3%)
6 to 12 years and 11 months     283 (61.7%)
HIV - transmission
Vertical 387 (84.3%)
Blood transfusion 18 (3.9%)
Indeterminate     54 (11.7%)
Origin
Referred from Hospitals 362 (79.0%)
Household     97 (21.0%)
Antiretroviral therapy
2 NRTI PI 133 (29.0%)
NRTI NNRTI PI 90 (19.6%)
AZT DDI 45 (9.8%)
AZT 3TC 82 (17.9%)
AZT only 90 (19.6%)
DDI only 19 (4.2%)
NRTI = Nucleoside Reverse Transcriptase Inhibitor: Zidovudine (AZT), 
Didanosine (DDI), Lamivudine (3TC); PI = Protease Inhibitor: Indinavir, 
Ritonavir, Saquinavir, Nelfinavir; NNRTI = Non-Nucleoside Reverse 
Transcriptase Inhibitor: Nevirapine, Efavirenz.
Table 2. Distribution of the 459-children sample into immune classes according to the age group and use or not of HAART.
Age group
0 to 5 years and 11 months (n = 176) 6 to 12 years and 11 months (n = 283)
Immune class    HAART (n = 70) ART (n = 106) HAART  (n = 153) ART (n = 130)
A1 12 (17,1%) 5 (4,7%) 54 (35,3%) 22 (16,9%)
A2 32 (45,7%) 21 (19,8%) 28 (18,3%) 13 (10,0%)
A3 1 (1,4%) - - -
B1 1 (1,4%) - 36 (23,5%) 24 (18,5%)
B2 19 (27,1%) 42 (39,6%) 24 (15,7%) 37 (28,5%)
B3 1 (1,4%) 3 (2,8%) - 1 (0,8%)
C1 - - 1 (0,7%) -
C2 3 (4,3%) 26 (24,5%) 7 (4,5%) 26 (20,0%)
C3 1 (1,4%) 9 (8,5%) 3 (2,0%) 7 (5,4%)
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Tables 4 and 5 present the mean serum CD4+ T 
lymphocyte counts in each age group. In the 0 to 5 years 
and 11 months age group children with chronic rhinosi-
nusitis had serum CD4+ T lymphocyte counts on average 
65.4 ±58 x 10-9cell/L below the count of children without 
rhinosinusitis (p = 0.002). There were no statistically 
significant differences among the mean serum CD4+ T 
lymphocyte counts among patients with or without acute 
rhinosinusitis in this age group.
In children aged from 6 to 12 years and 11 months, 
those with acute rhinosinusitis had serum CD4+ T lym-
phocyte counts on average 173.3 ±42 x 10-9cell/L above 
the count of similarly aged children without acute rhino-
sinusitis (p < 0.001); children with chronic rhinosinusitis 
had CD4+ T lymphocyte counts on average 154.2 ±39 
x 10-9cell/L below the count of similarly aged children 
without chronic rhinosinusitis.
Children given HAART had mean counts above the 
counts of children given ART, regardless of the age group; 
these differences were statistically significant (p < 0.001) 
and are shown on Table 6.
DISCUSSION
Chronic rhinosinusitis tem has been reported as a 
frequent disease in HIV-infected adult patients.4,5 Its pre-
Table 3. Prevalences of rhinosinusitis in the sample children according to age and use or not of HAART.
Age group
0 to 5 years and 11 months         6 to 12 years and 11 months
HAART (n=70) ART (n=106) p HAART (n=153) ART (n=130) p
Acute rhinosinusitis    9 (12.9%) 2 (1.9%) 0.007 11 (7.2%) 8 (6.2%) 0.9
Chronic rhinosinusitis  3 (4.3%) 10 (9.4%) 0.3 13 (8.5%) 10 (7.7%) 1.0
Total 12 (17.1%) 12 (11.3%) 0.4 24 (15.7%) 18 (13.8%) 0.8
HAART = Highly Active Anti-Retroviral Therapy
Table 4. Serum CD4+ T lymphocyte counts according to the pre-
sence of rhinosinusitis in children aged from 0 to 5 years and 11 
months.
     0 to 5 years and 11 months (n = 176)
Rhinosinusitis    CD4 (x10-9 cell/L) p
Acute 
Yes (n = 11) 
No (n = 165)
846,9 ± 174,6 
781,5 ± 189,5
0,3
Chronic 
Yes (n = 13) 
No (n = 163)
633,8 ± 187,7  
797,7 ± 184,1
0,002
Table 5. Serum CD4+ T lymphocyte counts according to the pre-
sence of rhinosinusitis in children aged from 6 to 12 years and 11 
months.
6 to 12 years and 11 months
(n = 283)
Rhinosinusitis CD4 (x10-9 cell/L) P
Acute 
Yes (n = 19) 
No (n = 264)
665,3 ± 131,1  
492,0 ± 183,1
<0,001
Chronic 
Yes (n = 23)
No (n = 260)
362,0 ± 136,4
516,2 ± 183,8
<0,001
Table 6. Serum CD4+ T lymphocyte counts according to the age group and use of HAART.
Age group
0 to 5 years and 11 months
(n = 176)
6 a 12 anos e 11 meses 
(n = 283)
CD4 (x 10-9 cell/L) p CD4 (x 10-9 cel/L) p
HAART (n = 223) 872,7 ± 158,1 <0,001 539,1 ± 166,8 <0,001
ART (n = 236) 728,1 ± 186,0 461,9 ± 197,1
HAART = Highly Active A
74
Brazilian Journal of otorhinolaryngology 75 (1) January/feBruary 2009
http://www.rborl.org.br  /  e-mail: revista@aborlccf.org.br
valence, however, varies according to the study, probably 
due to different diagnostic methods for rhinosinusitis and 
different methods.4,7 There are few published papers on 
the prevalence of rhinosinusitis in HIV-infected children; in 
these, results vary widely. Mofenson et al. found a 10.6% 
prevalence in 376 HIV-positive children. Chen et al. found 
a 20% prevalence in his series.12 Chaloryoo et al. studied 
250 Thai children with AIDS and found a 0.8% prevalence.13 
The prevalence of chronic rhinosinusitis among the 459 
HIV-infected children referred to otorhinolaryngological 
evaluation in our study was 7.8%. Chaloryoo’s low pre-
valence stands out among these numbers. This may be 
explained by the fact that his series consisted of children 
with full-blown AIDS, therefore with more significant me-
dical intercurrences such as hepatosplenomegaly (82.85%) 
and persistent pneumonia (64.4%). In this situation chronic 
rhinosinusitis may have been underdiagnosed.
It should be said that all patients in our study were 
being given antiretroviral therapy, albeit in heterogeneous 
regimens. In 1991, the Brazilian government started distri-
buting Zidovudine free of charge to HIV-infected patients; 
the Law 9313/96 establishes that 100% of HIV-infected 
patients are assured free antiretroviral therapy, including 
protease inhibitors.
The prevalence in our series was higher in older 
children, which would be expected since the paranasal 
sinuses in younger children are not always fully develo-
ped.
There are no published studies comparing the pre-
valence of rhinosinusitis according to the type of antire-
troviral therapy (HAART or ART). In our sample, children 
aged below 5 years and 11 months and given HAART had 
a higher prevalence of acute rhinosinusitis, thus a com-
paratively lower tendency to chronify. This may be due 
to the restoration of immune function in these children, 
who therefore respond more rapidly to germs in the pa-
ranasal cavities. Mizziara et al. studied the prevalence of 
otitis and found similar results: the prevalence of acute 
otitis media in the same age group was higher in children 
given HAART.14
The lack of any statistically significant difference in 
the prevalence of acute and chronic rhinosinusitis among 
children aged over 6 years, given HAART or ART, does 
not in itself suggest failure of highly active therapy (or 
even non-compliance to therapy); children who tended 
to chronify had lower mean serum CD4+ T lymphocyte 
counts.
Children with chronic rhinosinusitis in both age 
groups had lower serum CD4+ T lymphocyte counts com-
pared to those without chronic rhinosinusitis. Castillo et 
al. studied adult patients with chronic rhinosinusitis and 
concluded that relapses were more frequent in patients 
with serum CD4+ T lymphocyte counts below 200/mL.15 
In Barcelona, García-Rodríguez et al. studied 74 adult 
HIV-positive patients and found that low serum CD4+ T 
lymphocyte counts were associated with rhinosinusitis.16 
Mofenson et al. studied 376 HIV-infected children and 
found that serum CD4+ T lymphocyte counts were not 
different in children with and without rhinosinusitis.17 In 
this study, the authors did not separate children with acute 
or chronic rhinosinusitis. The sample consisted mainly 
of younger children with acute rhinosinusitis. Mofenson 
et al.’s results are thus similar to ours in the group aged 
below 5 years and 11 months with acute rhinosinusitis; in 
this subgroup, serum CD4+ T lymphocyte counts were not 
different among children with and without rhinosinusitis 
(Table 4).
In our series the use of HAART improved the im-
mune system of these children; their mean serum CD4+ 
T lymphocyte counts were higher compared to children 
given ART (Table 6).
Many factors may be involved for a nasosinusal 
condition to become chronic, such as the presence or 
absence of allergies or anatomical features that hinder the 
success of standard medical therapy.18
FINAL COMMENTS
Our results show that rhinosinusitis in children aged 
below 5 years tended to chronify less often, probably 
due to an improved immune system. It should be noted, 
however, that given the cross-sectional nature of our 
study, these results do not imply causality. The number 
of children with rhinosinusitis was not that high, which 
may explain the lack of statistical significance in older 
children. Additional prospective studies are needed to 
assess more effectively the effect of HAART on the onset 
of rhinosinusitis in children.
In general these objections do not invalidate our 
study; it is, undoubtedly, one of the largest series of rhi-
nosinusitis in HIV-infected Brazilian children.
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